Saturday, November 21, 2026 Never miss a recall or a rule change Get the free brief →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
Business & M&ADaewoong Q3 profit up 43.5% on Nabota exports2 days agoMarketAllergan posts nine ASDS abstracts, two on GLP-1 patientslast weekBusiness & M&AEvolus eyes Sculpt filler launch in Q1 20274 days agoBusiness & M&AGalderma lifts 2026 sales outlook to 22.5-23.5%last weekBusiness & M&AInMode Q3 revenue holds near $92.1M, margins sliplast weekBusiness & M&ACytrellis Brings ellacor into UM Nurse Practitioner Courselast weekRegulatoryMexico approves Restylane Shaype for jawline firstlast weekRegulatoryFDA clears Shenzhen Bway red/NIR LED face masklast weekBusiness & M&ACoty shareholders approve 50M-share equity plan boostlast weekRegulatoryTrifluent recalls Tridacaine III lidocaine patchlast weekDevices & TechConexeu's first human collagen batch meets its own specslast weekBusiness & M&AMedytox Q3 operating profit up 74.5% on toxin saleslast week
Regulatory

Galderma Receives Complete Response Letter for Relfydess — Botox Rival Faces Regulatory Hurdle

FDA rejects Galderma's new neuromodulator formulation; shares slide on failed market-entry bid.

A scientist conducting experiments in a red-lit laboratory with various lab equipment.
Photo: Artem Podrez / Pexels
1-YEAR MOVE
+15% −13%
ABBV ▲11.6%
1-year price move by ticker
TickerCompany1-year change
ABBVAbbVie (Allergan Aesthetics)+11.6%

Get the free Inside MedSpa brief by email

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Galderma has received a Complete Response Letter (CRL) from the FDA for Relfydess (relbotulinumtoxinA), its novel botulinum toxin formulation intended as a Botox alternative. The CRL indicates the agency requires additional data or clarification before approval can be granted, effectively blocking the product's U.S. market entry in the near term.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

FDA Complete Response Letter blocks Relfydess market entry; Galderma's neuromodulator expansion stalls.

Relfydess was positioned as a differentiated neuromodulator with a potentially faster onset and longer duration than existing toxins, but the regulatory pathway proved more complex than anticipated. The setback underscores the high bar for new-entity botulinum toxin approvals and the entrenched competitive advantage of AbbVie's Botox and Galderma's own Dysport. For practices, this means no near-term disruption to toxin pricing or supply dynamics; the neuromodulator market remains dominated by two players with limited new competition on the horizon.

Source: original report ↗

Frequently asked questions

What is Relfydess and why did the FDA reject it?

Relfydess is Galderma's novel botulinum toxin formulation designed as a Botox alternative with potentially faster onset and longer duration. The FDA issued a Complete Response Letter (CRL), meaning the agency requires additional data or clarification before approval—effectively blocking U.S. market entry in the near term.

Will Relfydess rejection affect Botox pricing or supply?

No. The rejection means no near-term disruption to toxin pricing or supply dynamics. The neuromodulator market remains dominated by Botox (AbbVie) and Dysport (Galderma), with limited new competition on the horizon.

How hard is it to get FDA approval for a new botulinum toxin?

Very hard. Relfydess's rejection underscores the high regulatory bar for new-entity botulinum toxin approvals. The entrenched competitive advantage of existing players like Botox and Dysport makes market entry significantly more complex than anticipated.

What does a Complete Response Letter mean for a drug approval?

A Complete Response Letter (CRL) indicates the FDA cannot approve the drug in its current form and requires additional data, clarification, or further studies before resubmission. It effectively delays or blocks market entry until the company addresses the agency's concerns.

When might Relfydess become available if Galderma resubmits?

The timeline is unclear. Galderma must first gather additional data or clarification to address the FDA's concerns, then resubmit—a process that typically takes months to years depending on the complexity of the issues raised in the CRL.

Business information, not medical or legal advice. Verify product status at FDA.gov.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Share

https://insidemedspa.com/article/galderma-relfydess-fda-complete-response-letter/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa · Free brief

    By the time it's news, it's too late.

    FDA decisions, recalls and the rules you operate under, drafted from the source documents and sent free by email.

    Get the free brief The free Inside MedSpa brief · no card · unsubscribe anytime.
    FDA, recalls and rule changes for practice owners Get the free brief →